Characteristics of patients continuing and discontinuing nintedanib in the year following commencement

CharacteristicContinued nintedanibDiscontinued nintedanibp-value
Patients n8569
Age at treatment commencement years69.6±8.273.0±7.00.007
Male69 (81.2)55 (79.7)0.819
FVC % predicted77.1±17.267.0±18.80.001
DLCO % predicted45.2±14.640.6±14.80.07
Domiciliary oxygen18 (21.2)26 (37.7)0.024
Time since diagnosis months11.7±15.116.4±17.50.08
Prior pirfenidone treatment23 (27.1)27 (39.1)0.112

Data are presented as mean±sd or n (%), unless otherwise stated. FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide.